NTLA vs. BMY
Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NTLA or BMY.
Correlation
The correlation between NTLA and BMY is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NTLA vs. BMY - Performance Comparison
Key characteristics
NTLA:
-0.85
BMY:
0.60
NTLA:
-1.21
BMY:
1.12
NTLA:
0.86
BMY:
1.14
NTLA:
-0.58
BMY:
0.37
NTLA:
-1.31
BMY:
1.51
NTLA:
42.13%
BMY:
11.62%
NTLA:
65.04%
BMY:
29.17%
NTLA:
-94.79%
BMY:
-70.62%
NTLA:
-93.12%
BMY:
-24.30%
Fundamentals
NTLA:
$1.24B
BMY:
$113.30B
NTLA:
-$5.45
BMY:
-$4.41
NTLA:
-0.10
BMY:
1.26
NTLA:
$45.00M
BMY:
$48.30B
NTLA:
$39.89M
BMY:
$32.20B
NTLA:
-$390.10M
BMY:
$3.16B
Returns By Period
In the year-to-date period, NTLA achieves a 4.37% return, which is significantly higher than BMY's -0.20% return.
NTLA
4.37%
10.54%
-48.50%
-55.22%
-1.90%
N/A
BMY
-0.20%
-2.21%
18.64%
14.20%
0.38%
2.23%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NTLA vs. BMY — Risk-Adjusted Performance Rank
NTLA
BMY
NTLA vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NTLA vs. BMY - Dividend Comparison
NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.33%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.33% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
NTLA vs. BMY - Drawdown Comparison
The maximum NTLA drawdown since its inception was -94.79%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY. For additional features, visit the drawdowns tool.
Volatility
NTLA vs. BMY - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 22.33% compared to Bristol-Myers Squibb Company (BMY) at 8.69%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NTLA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities